anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants with non-squamous cell carcinoma will receive QL1706, bevacizumab, pemetrexed, and carboplatin by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with QL1706, bevacizumab and pemetrexed until unacceptable toxicity or loss of clinical benefit.
Beginning 1 hour before surgery, patients receive tozuleristide intravenously (IV) over 1-5 minutes. Patients then surgical resection per standard of care and undergo near infrared (NIR) imaging with standard of care device.
The highest incidence of sepsis across all age groups occurs in neonates leading to substantial mortality and morbidity. Cardiovascular dysfunction frequently complicates neonatal sepsis including biventricular systolic and/or diastolic dysfunction, vasoregulatory failure, and pulmonary arterial hypertension. The haemodynamic response in neonatal sepsis can be hyperdynamic or hypodynamic and the underlying pathophysiological mechanisms are heterogeneous. The diagnosis and definition of both neonatal sepsis and cardiovascular dysfunction complicating neonatal sepsis are challenging and not consensus-based. Future developments in neonatal sepsis management will be facilitated by common definitions and datasets especially in neonatal cardiovascular optimisation. IMPACT: Cardiovascular dysfunction is common in neonatal sepsis but there is no consensus-based definition, making calculating the incidence and designing clinical trials challenging. Neonatal cardiovascular dysfunction is related to the inflammatory response, which can directly target myocyte function and systemic haemodynamics.
1. Technical Result Increase in therapeutic efficiency and widening of assortment of expectoration means. 2. Essence An expectoration means comprises a sum of polysacharides – mukaltin obtained from land part of Althaea officinalis L., tartaric acid, extract of wild strawberry and raspberry fruits and sugar syrup. 3. Field of Application Medicine, pharmaceutical industry.
Adjunctive Therapy for Partial-Onset Seizures in Adult Patients

The efficacy of pregabalin as adjunctive therapy for partial-onset seizures in adult patients was established in three 12-week, randomized, double-blind, placebo-controlled, multicenter studies. Patients were enrolled who had partial-onset seizures with or without secondary generalization and were not adequately controlled with 1 to 3 concomitant antiepileptic drugs (AEDs). Patients taking gabapentin were required to discontinue gabapentin treatment 1 week prior to entering baseline. During an 8-week baseline period, patients had to experience at least 6 partial-onset seizures with no seizure-free period exceeding 4 weeks. The mean duration of epilepsy was 25 years in these 3 studies and the mean and median baseline seizure frequencies were 22.5 and 10 seizures per month, respectively. Approximately half of the patients were taking 2 concurrent AEDs at baseline. Among the pregabalin -treated patients, 80% completed the double-blind phase of the studies.

Table 11 shows median baseline seizure rates and median percent reduction in seizure frequency by dose.

In the first study (E1), there was evidence of a dose-response relationship for total daily doses of pregabalin between 150 mg/day and 600 mg/day; a dose of 50 mg/day was not effective. In the first study (E1), each daily dose was divided into two equal doses (twice a day dosing). In the second study (E2), each daily dose was divided into three equal doses (three times a day dosing). In the third study (E3), the same total daily dose was divided into two equal doses for one group (twice a day dosing) and three equal doses for another group (three times a day dosing). While the three times a day dosing group in Study E3 performed numerically better than the twice a day dosing group, this difference was small and not statistically significant.

A secondary outcome measure included the responder rate (proportion of patients with greater than or equal to 50% reduction from baseline in partial seizure frequency). The following figure displays responder rate by dose for two of the studies.

Figure 6: Responder Rate by Adjunctive Epilepsy Study

Figure 7: Seizure Reduction by Dose (All Partial-Onset Seizures) for Studies E1, E2, and E3

Subset evaluations of the antiseizure efficacy of pregabalin showed no clinically important differences as a function of age, gender, or race.

Pediatric use information is approved for Pfizer’s LYRICA (pregabalin) Capsules and Oral Solution products. However, due to Pfizer’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
OBJECTIVE: Chronic hepatitis B (CHB) virus infection remains a major public health concern. In this study, the diagnostic capability of C-X-C chemokine receptor type 4 promoter methylation in patients with CHB-associated liver fibrosis/cirrhosis was evaluated.
METHODS: Two hundred participants were recruited, including 25 healthy controls (HCs), 60 patients with CHB and 115 patients with hepatitis B virus (HBV)-related liver fibrosis/LC. Researchers monitored the methylation and messenger ribonucleic acid (mRNA) levels of C-X-C chemokine receptor type 4 (CXCR4) in peripheral blood mononuclear cells (PBMCs). In addition, we utilized single cell sequencing to analyze the cell types highly expressing CXCR4 in HBV-related liver fibrosis/LC.
RESULTS: HBV-related fibrosis/cirrhosis patients exhibited a significant elevation in the expression level of CXCR4 mRNA in PBMCs compared to CHB ones. The CXCR4 promoter showed a significantly lower methylation level in patients with CHB-related fibrosis/cirrhosis than in patients with CHB. Additionally, the diagnostic area under the area under the curve (AUC) of methylation of the CXCR4 promoter for CHB -related liver fibrosis/LC exceeded liver stiffness measurement (LSM), aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis-4 score (FIB-4). Furthermore, single-cell analysis demonstrated that CXCR4 expression is closely associated with Natural Killer cells(NK cells), T lymphocytes (T cells), and monocytes.
CONCLUSION: The low methylation of the CXCR4 promoter holds promise as a non-invasive biomarker for detecting CHB-associated liver fibrosis/LC.
Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level; Group 3 participants will also take HAART for 3 days prior to the start of each aldesleukin cycle, throughout the 5-day aldesleukin cycle, and for 2 days after the end of each aldesleukin cycle (for a maximum of 10 days with each aldesleukin cycle). Some Group 3 participants may take part in additional cycles of aldesleukin if they meet certain study criteria. HAART is not supplied by the study, and choice of drugs is left to the participant and physician. The HAART regimen should include at least one protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors.
PURPOSE: A composition containing as an effective ingredient a herbal extract of Sungisan(prescribed according to the representative oriental medical publications of "Dong-I Bogam") is provided. The composition displays little hepatotoxicity while inhibiting weight gain and reducing blood sugar levels and can be used as a drug and a health supplementary food for prevention and treatment of diabetes and complications associated with diabetes. CONSTITUTION: A pharmaceutical composition contains 0.5 to 50% by weight of Sungisan(prescribed according to the representative oriental medical publications of "Dong-I Bogam") and a pharmaceutically acceptable carrier, based on the total weight of the composition. The Sungisan contains a mixed extract of Magnoliae Cortex, Rhei Rhizoma and Ponciri Fructus in a ratio of 1 to 10:1 to 10:1 to 10. The composition inhibits the increase of blood sugar levels, reduces the decrease of total cholesterol and LDL-cholesterol levels and exhibits excellent antidiabetic activity. The complications associated with diabetes are caused by increase of neutral lipid, cholesterol and high-density lipid.
The invention relates to a method for production of a polyphenol complex possessing anabolic activity. The herb of Soja hispida is extracted with water followed by filtration and drying. The extraction is carried out seven times at the temperature of 44-46°С for one hour at the 1:9 - 1:11 ratio of raw material : extractant. The combined extracts are allowed to settle for one day followed by the filtration. The supernatant is dried. The substance with marked anabolic activity without side effects is produced, which can be used as an active ingredient of anabolic pharmaceuticals in various dosage forms.
The invention discloses a lymph node benign and malignant lesion auxiliary diagnosis method based on a multi-modal ultrasound image. The method comprises the following operation steps: first, the B-mode ultrasound image and the real-time elastoultrasound imaging image are preprocessed. And secondly, utilizing a computer algorithm to respectively extract quantitative characteristics of the focus in the conventional B-type ultrasonic image and the real-time elastic imaging image. Then, a plurality of feature selection algorithms are used for carrying out feature selection on the quantized features of the two modes. And finally, model fusion, namely, respectively classifying the benign and malignant lymph nodes by using a Support Vector Machine (SVM) for six feature sets obtained by the two modes through different feature selection algorithms. The probability of SVM classification, which is a posterior probability between 0 and 1, representing the likelihood of a lymph node being classified into each class, is then obtained using a sequence minimum optimization algorithm. And then, combining six trained SVM classifier models by using Adaboost with a decision tree as a basic weak learning algorithm to improve the performance and obtain a classification result.
Cerebellar rTMS. 1Hz repetitive transcranial magnetic stimulation (rTMS) to cerebellar vermis.
The invention discloses a burn rapid healing Chinese medicine ointment for treating burns. The burn rapid healing Chinese medicine ointment is prepared from 19 Chinese herbal medicines of garden burnet root, giant knotweed rhizome, pearl, catechu, goldthread, borax, fresh aloe, burdock, herba orostachyos, garden balsam stem, borneol, storesin, gypsum (ustulation), dragon's bones (ustulation), oyster (ustulation), calcined alum, beeswax, white wax and sesame oil. The burn rapid healing Chinese medicine ointment has reasonable composition and precise and appropriate compatibility, and the preparation method is unique. Various burns and scalds can be rapidly healed by applying the medicinal ointment, the burn rapid healing Chinese medicine ointment has rapid and thorough acesodyne effects, strong infection resistance, strong sarcogenic promoting capacity and high healing-promotion speed, normal skins can be grown from epibiotic skin stem cells on the roots of hair follicles, and a wound skin have no residual scarring and pigment or loss after healing. The burn rapid healing Chinese medicine ointment is convenient to use, simple to prepare, and low in preparation cost. For the past thirty years, the burn rapid healing Chinese medicine ointment is used by more than four thousands of various burn patients, has 100% of effective rate and 99% of cure rate, has favorable market prospect and development value, and is a burn rapid healing Chinese medicine ointment worth to be popularized.
Ranibizumab 0.5 mg intravitreal injection 0.5 mg in the study eye on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment.
The invention provides a rabbit bordetella bronchiseptica genetic engineering subunit vaccine. The amino acid sequence of antigens is SEQ ID NO:1. Through PCR amplification of a main protective antigen gene PPP of QDBb01 rabbit bordetella bronchiseptica strain, genetic engineering recombinant escherichia coli BL21 host bacteria capable of expressing the main protective antigen gene PPP of rabbit bordetella bronchiseptica are conducted through PET32a(+)expression vectors. Through SDS-PAGE analysis, a 46.2 kDa recombined and fused target protein is expressed. The fused protein is purified and renatured and then prepared into the genetic engineering subunit aluminium hydroxide gel vaccine. The subunit vaccine is injection into a domestic rabbit with the weight being about 1.5 kg in a subcutaneous mode for immunization according to the dosage of 1.0 ml for each rabbit, after 14 days, challenge is conducted through the QDBb01 rabbit bordetella bronchiseptica strain according to 100LD50, and the protection ratio is 10/10.
OBJECTIVES: This study focused on children with confirmed methicillin-resistant Staphylococcus aureus (MRSA) infections to determine MRSA screening utility in guiding empirical anti-MRSA treatment of children without history of MRSA infection. We examined the concordance of screens to assess differences by infection type and used statistical analysis to determine significant contributors to concordance.
METHODS: Pediatric hospital patients admitted from 2002 through 2022 were included. Subjects had MRSA infections subsequent to MRSA surveillance screens performed the preceding year. Statistical analysis identified associations between MRSA screens and infections. Number needed to treat analysis calculated the utility of rescreening.
RESULTS: Among 246 subjects, 39.0% had concordant screens; 151 (61.4%) screens were obtained in the 2 weeks preceding infection. Sensitivity for bacteremia was 50.0% (n = 42), for endotracheal/respiratory 44.4% (n = 81), and 29.4% (n = 102) for skin and soft-tissue infection. For children aged younger than 6 months, sensitivity was 35.9% (n = 78). Multivariable analysis significantly associated days since screening with decreasing likelihood of concordance. Regression modeled the probability of concordance to drop below 50.0% for all infections after 4 days, after 6 days for bacteremia specifically, and 12 days for endotracheal/respiratory infections.
CONCLUSIONS: The concordance of screens was far lower than negative predictive values found previously; earlier studies were possibly impacted by low prevalence and exclusion of children at high risk to inform high negative predictive values. We suggest that negative MRSA screens should not invalidate reasonable suspicion for MRSA infection in patients with high pretest probabilities.
PURPOSE: To report the surgical outcome of synovial osteochondromatosis, a rare tumor of the cervical spine, in a 6-year-old boy.
METHODS: A 6-year-old boy presented with muscle weakness in the right deltoid (2) and biceps (4) during a manual muscle test. Magnetic resonance imaging showed a 3 × 2 × 1.5 cm mass within the spinal canal at the C4-6 level, compressing the cervical spinal cord from the right side. Computed tomography revealed hyperintense areas within the tumor and ballooning of the right C4-5 and C5-6 facet joints.
RESULTS: After a biopsy confirmed the absence of malignancy, a gross total resection was performed. The pathological diagnosis of synovial osteochondromatosis was established. Postoperatively, muscle weakness improved fully in the manual muscle test, and there were no neurological findings after 3 months. However, the patient is under careful follow-up owing to the detection of a regrowth site within the right C4-5 and C5-6 intervertebral foramen 2 years postoperatively.
CONCLUSIONS: Synovial osteochondromatosis of the cervical spine in children is rare, and this is the first report of its regrowth after surgery. Synovial osteochondromatosis should be included in the differential diagnosis of pediatric cervical spine tumors.
A long-term, multi-centre, open label, non-comparative phase III study in patients with atopic dermatitis. All centres in Europe which have participated or are still participating in the FG-506-06-12, FG-506-06-18 or FG-506-06-19, FG-506-06-22 or FG-506-06-23 studies will be offered a participation in the protocol. Only patients enrolled by those centres for the above mentioned studies, who have received at least one dose of study medication can be enrolled. Tacrolimus ointment 0.1% will be administered until clearance of the skin occurs. Treatment is restarted after signs and symptoms reoccur. Safety will be assessed from adverse events reported by the patient/parent/guardian or observed by the investigator at the site of application and elsewhere. The safety evaluation will include monitoring of routine hematology and serum chemistry parameters at Baseline/Day 1, Week 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36, Month 42 and/or at the end of the study (End-of-Study Visit).
In the genesis and progression of cardiovascular diseases involving both innate and adaptive immune responses, inflammation plays a pivotal and dual role. Studies in experimental animals indicate that certain immune responses are protective, while others exacerbate the disease. T-helper (Th) 1 cell immune responses are recognized as key drivers of inflammatory progression in cardiovascular diseases. Consequently, the CD4+CD25+FOXP3+ regulatory T cells (Tregs) are gaining increasing attention for their roles in inflammation and immune regulation. Given the critical role of Tregs in maintaining immune-inflammatory balance and homeostasis, abnormalities in their generation or function might lead to aberrant immune responses, thereby initiating pathological changes. Numerous preclinical studies and clinical trials have unveiled the central role of Tregs in cardiovascular diseases, such as atherosclerosis. Here, we review the roles and mechanisms of Treg subsets in cardiovascular conditions like atherosclerosis, hypertension, myocardial infarction and remodeling, myocarditis, dilated cardiomyopathy, and heart failure. While the precise molecular mechanisms of Tregs in cardiac protection remain elusive, therapeutic strategies targeting Tregs present a promising new direction for the prevention and treatment of cardiovascular diseases.
µ-Opioid receptor agonists, the gold standard for analgesia, come with significant side effects when used chronically. Tolerance, defined as the decrease in analgesic activity after repeated use, remains a vital therapeutic obstacle as it increases the likelihood of dose escalation and potentially lethal side effects like respiratory depression. Previous experiments have shown that the endomorphin-1 analog, ZH853, is a specific µ-opioid receptor agonist with reduced side effects like tolerance and glial activation following chronic central administration in pain-naive animals. Here, we investigated the effects of chronic, peripheral administration of µ-opioid receptor agonists following neuropathic injury. Though µ-opioids are effective at reducing neuropathic pain, they are not recommended for first-line treatment due to negative side effects. Compared with chronic morphine, chronic ZH853 treatment led to decreased tolerance and reduced glial activation. Following twice-daily intravenous injections, morphine was less potent and had a shorter duration of antinociception compared with ZH853. Chronic morphine, but not chronic ZH853, elevated markers of activation/inflammation of astrocytes (glial fibrillary acidic protein), microglia (ionized calcium-binding adapter molecule 1), the proinflammatory cytokine tumor necrosis factor-α, and phosphorylated mitogen-activated protein (MAP) kinase p38 (pp38). By contrast, chronic ZH853 reduced ionized calcium-binding adapter molecule 1 and tumor necrosis factor-α relative to both morphine and vehicle, suggesting anti-inflammatory properties with respect to these markers. Glial fibrillary acidic protein and pp38 were not significantly different from vehicle but were significantly lower than morphine. This study demonstrates the effectiveness of chronic ZH853 for providing analgesia in a neuropathic pain state with reduced tolerance compared with morphine, potentially due to reductions in spinal glial activation. PERSPECTIVE: Neuropathic pain is generally undertreated and resistant to medication, and side-effects limit opioid treatment. Here, we show that, compared with an equiantinociceptive dose of morphine, chronic intravenous administration of endomorphin analog ZH853 led to prolonged antiallodynia, reduced tolerance, and inhibition of spinal cord neuroinflammation in male spared nerve-injured rats.
PURPOSE:To enable application of lectin to all antigens including sugar chains by conjugating an antigen material to a carrier with lectin as a coupling agent. CONSTITUTION:Coneanavalin A25mug/ml liquid is added at an equal amt. to, for example, 2% raw red blood cell liquid of goat and is brought into reaction therewith, by which a goat red blood cell-lectin conjugate is obtd. Such conjugate is adjusted with a phosphoric acid buffer soln. (PBS) to 2% concn. and an equal amt. of influenza virus is added thereto to obtain the sensitized red blood cells for single radial hemolysis (SRH) in conformity with the concn. meeting the purpose of use. 1.5ml such sensitized red blood cell liquid and 1.8ml 2% agarose as well as 0.7ml PBS are mixed in a thermostatic chamber kept at 40- 45 deg.C and after 1.3ml such liquid mixture is injected into a 26X37mm. tray and is solidified, a hole of 3.5mm. diameter for measuring specimen is punched and a plate for SRH is obtd. A specimen is added at 10mul thereto and a complement film is superposed thereon and the SRH is determined from the hemolytic ring obtd. by bringing the specimen into reaction for 1-2hr at 35 deg.C after resting the same for 16-20hr at 4-10 deg.C.
Whole brain radiotherapy will be applied with a total dose of 20 Gy in 10 fractions (single dose of 2 Gy). OSC as needed.
For this study, 274 patients with TA-AAD admitted into our hospital between February 2019 and July 2021 were enrolled retrospectively. A total of 54 patients deceased unfortunately within 1 month following surgery. We compared baseline sociodemographic, clinical, and functional status based on the main outcome using t tests or Mann-Whitney U test for continuous data and χ2 or Fisher's exact tests for categorical data. Continuous variables were expressed as mean SD median depending on the normality of distribution, and categorical variables were expressed as absolute number along with their percentages and compared using the chi-square test. Multivariate regression analysis was applied to assess the association between EOS and 1-month mortality in an unadjusted model, in an age-, sex-, Body mass index (BMI)-adjusted model (model 2), adjusted for age, sex, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP) (model 3), and further adjusting for age, sex, BMI, SBP, DBP, MAP, heart rate (HR), diabetes, stroke and hyperlipidemia (model 4). In addition, the general linear model repeated-measures ANOVA analysis (Corrected by Greenhouse-Geisser test in nonspherical cases) was used to compare preoperative EOS and postoperative eight-days EOS. For prognostic analysis, receiver-operating characteristics (ROC) curves were used to determine the optimal cutoff of EOS at different points and the time of postoperative EOS to return to normal levels for the prognostic events. A Kaplan-Meier curve was then applied to compare the prognosis between the 2 subgroups based on the predictive threshold. A P value\<0.05 was regarded as statistically significant for all statistical tests.